Introduction Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 References

A Clinical Guide to Urine Drug Testing. Augmenting Pain Management & Enhancing Patient Care. Accessed February 1, 2010 at:

Braithwaite R, Jarvie D, Minty P, Simpson D, Widdop B. Screening for drugs of abuse, I: Opiates, amphetamines and cocaine. Ann Clin Biochem. 1995;32:123-153.

Chou R, Fanciullo G, Fine P, Miaskowski G, Passik S, Portenoy P. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:131-146.

Compton P. The Role of Urine Toxicology in Chronic Opioid Analgesic Therapy. Pain Manag Nurs. 2007;8:166-172.

Cook JD, Strauss KA, Caplan YH, Lodico CP, Bush DM. Urine pH: The Effects of Time and Temperature after Collection. J Anal Toxicol. 2007;31:486-496.

Dasgupta A. The effects of adulterants and selected ingested compounds on drugs-of-abuse testing in urine. Am J Clin Pathol. 2007;128:491-503.

Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27:260-267.

Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18:S76-S82.

Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, Fanciullo GJ. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:1097-1102.

Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37:301-314.

Von Seggern RL, Fitzgerald CP, Adelman LC, Adelman JU. Laboratory monitoring of OxyContin (oxycodone): Clinical Pitfalls. Headache. 2004;44:44-47.

Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. Opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8:573-584.